RAHWAY, N.J. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO) today announced ...
Enrollment completed with 73 patients in April 2022 Of the 32 patients treated with bomedemstat for more than 24 weeks: 97% (31/32) achieved platelet count reduction to ≤400 x 109/L. 94% (30/32) ...
Merck is shoring up its drug pipeline with the $1.35 billion buyout of Imago BioSciences, a biotech developing blood and bone marrow disorder therapies that could offer advantages over currently ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Imago BioSciences, Inc. (“Imago”), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms ...
- As of the data cutoff of 18 October 2022, bomedemstat demonstrated spleen volume reduction in 66% (33/50) of patients and reduction in total symptom score in 65% (17/26) of patients at 24 weeks - - ...
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Imago is a clinical stage biopharma company focused on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results